Gilead Sciences, Inc. (GILD)

About Gilead Sciences, Inc.

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

As of November 3, 2026, Gilead Sciences, Inc. (GILD) stock edged higher to $170.82, up 0.29% (+$0.49) versus the previous close. On the day, shares have traded between $168.75 and $171.47. That puts GILD near the top of its 52-week range of $116.88 to $175.65. Gilead Sciences, Inc. operates in the biological products, (no diagnostic substances) space and carries a market capitalization of roughly $211.70 billion, with about 764.2K shares changing hands.

Latest GILD news

• BioNTech Announces Third Quarter 2026 Financial Results and Corporate UpdateYahoo Finance· Nov 3, 6:45 AM ETL
• Gilead (GILD) Stock Fair Value Edges Higher After Analyst Target IncreasesYahoo Finance· Nov 2, 1:07 PM ET
• Former Gilead Head of U.S. Medical Affairs Dean Hakanson, MD, Joins GOA Therapeutics as Chief Medical OfficerYahoo Finance· Nov 2, 10:00 AM ET
• Should You Buy The Dip In Alnylam Stock?trefis.com· Nov 2, 9:39 AM ET
• Gilead to Present Late-Breaking Clinical Data and Real-World Evidence at HIV GlasgowYahoo Finance· Nov 2, 8:30 AM ET
• Why Did MO, GILD, XOM Stocks Surge To 52-Week Highs Last Week?stocktwits.com· Nov 1, 9:48 PM ET
• 1 Dividend-Paying Biotech Stock to Buy Hand Over Fist in Novemberfool.com· Nov 1, 4:02 PM ET
• GILD Q3 deep dive: HIV franchise drives growth as policy headwinds loomYahoo Finance· Oct 31, 3:07 AM ET

Source: Yahoo Finance RSS · Updated November 3, 2026

Want GILD headlines, alerts and AI research in one place? Create a free account →

• $SLS $GILD Just the Secondary asset is already worth 3x the current short rigged mcap. List of FDA Approved drugs based on Ph1/2 pivotal trial results - same stage as SLS009 will report this month or next. Top Line PIVOTAL Trial RESULTS for AML-MR Front Line Patients - This Qu…

  @55X_ROI_Q1_2026· Nov 3, 9:23 AM ET

• $SLS $GILD Just the Secondary asset is already worth 3x the current short rigged mcap. List of FDA Approved drugs based on Ph1/2 pivotal trial results - same stage as SLS009 will report this month or next. Top Line PIVOTAL Trial RESULTS for AML-MR Front Line Patients - This Qu…

  @55X_ROI_Q1_2026· Nov 3, 2:40 AM ET

• $SLS $GILD Oddly Coincidental the 80th Event was Announced on October 28 - but - but for the First Time ever, the co did not Time Stamp the actual date the Event Occurred --- in all other Event Milestone PR's the Date of the Event itself was included in the PR. Not this ti…

  @55X_ROI_Q1_2026· Nov 2, 11:10 PM ET· Bullish

• $SLS $GILD Why does SLS for the first time in Corp History have A MASSIVE BOOTH at the ASH Exhibition Hall? Late Breaker Abstract DEADLINE was OCT 28... The SAME DAY SLS announced the 80th - but no definition on WHEN the 80th occurred. -- Did they Submit GPS TOP LINE DATA ? wh…

  @55X_ROI_Q1_2026· Nov 2, 3:48 PM ET

• $SLS $GILD Why does SLS for the first time in Corp History have A MASSIVE BOOTH at the ASH Exhibition Hall? Late Breaker Abstract DEADLINE was OCT 28... -- Did they Submit GPS TOP LINE DATA ? which they easily could Pull, EVENT Rates by ARM for instance - is Known Immediately …

  @55X_ROI_Q1_2026· Nov 2, 3:33 PM ET

Source: Stocktwits. User posts are opinions, not verified facts. See what's trending →